| Literature DB >> 28985084 |
Paul Hermant1, Damien Bosc1, Catherine Piveteau1, Ronan Gealageas1, BaoVy Lam1, Cyril Ronco1, Matthieu Roignant1, Hasina Tolojanahary1, Ludovic Jean2, Pierre-Yves Renard2, Mohamed Lemdani3, Marilyne Bourotte1, Adrien Herledan1, Corentin Bedart1, Alexandre Biela1, Florence Leroux1, Benoit Deprez1, Rebecca Deprez-Poulain1,4.
Abstract
Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas. Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compounds in vitro. We designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are critical for plasma stability. Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids. Finally, we suggest structural features to be introduced or removed to improve stability. This work thus provides the first medicinal chemistry toolbox (experimental procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacological probes and therapeutic agents. This study is particularly relevant to preclinical development as it allows obtaining compounds equally stable in human and rodent models.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28985084 DOI: 10.1021/acs.jmedchem.7b01444
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446